Conversational AI organization Openstream.ai has announced a new patent for automated digital twin technology that enables EVA (enterprise virtual assistant) users to utilize virtual assistants that are digital twins of human experts in their fields.
Digital twins share human knowledge and unique personas to have empathetic, illusion-free conversations with end users.
The twins appear as AI-enabled avatars, virtual or voice agents to engage users in any language. Users can deploy the twin for customer support, employee help desk, and co-pilot use cases.
„The ability to build and deploy expert human digital twins within an enterprise has been the holy grail of AI efforts within the expert community for decades,“ said Raj Tumuluri, CEO of Openstream.ai. is a major milestone towards achieving this goal.“ said in a statement.
“More than just a talker, they are effective communicators with the ability to observe, understand, and engage on multiple levels, using the nuances of human conversation through facial expressions, intonation, and nonverbal cues. There has to be.”
bigger trends
The global digital twin market size in 2023 will be Estimation 16.75 billion and is projected to grow by 35.7% by 2030.
Openstream.ai was founded in 2008 and released its EVA virtual assistant platform in 2013.
Earlier this month, the New Jersey-based company announced a patent for collaborative, plan-based, speech-guided multimodal interactions. This technology allows virtual agents to understand user intent through multimodal input and generate interactions without scripting.
California-based metabolic health focused twin health announced in December Safe $50 million in funding led by Temasek with additional investments from Sofina, ICONIQ Growth, Peak XV and Helena.The company too collected Raised $140 million in Series C in 2021.
Clinical trial company using AI forget raised $50 million It will be hosted by Insight Partners in 2021.
company brought in It raised an additional $50 million in February this year, which the company will use to expand its data and invest in research and development and engineering capabilities.
Startup based in Singapore mesh bioProviding digital twin chronic disease management solutions, raised Raised $3.5 million in Series A funding in February. The funding round, led by East Ventures, aims to help Mesh Bio expand its solution deployment across Hong Kong and Southeast Asia.